NCT02656043 - A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel | Biotech Hunter

Enrollment

213

Participants

Timeline

Start Date

September 17, 2015

Primary Completion Date

February 16, 2017

Study Completion Date

March 17, 2017

Conditions

Acne Vulgaris

Interventions

DRUG

XPF-005

Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.

DRUG

Placebo

Trial Locations (20)

T2G 1B1

Kirk Barber Research, Calgary

T3A 2N1

Institute for Skin Advancement, Calgary

T5K 1X3

Stratica Medical Inc., Edmonton

V3R 6A7

Dr. Chih-ho Hong Medical Inc., Surrey

V5Z 4E1

Carruthers & Humphrey Clinical Research, Vancouver

V6E 4M3

Pacific Dermaesthetics, Vancouver

R3C 1R4

Toole Dermatology Research, Winnipeg

E2A 4Z9

Clinique Médicale Nepisiguit, Bathurst

L4M 7G1

SimcoDerm Medical and Surgical Dermatology Center, Barrie

L3P 1X2

Lynderm Research Inc, Markham

L5H 1G9

DermEdge Research, Mississauga

L6J 7W5

Research by ICLS, Oakville

L4C 9M7

York Dermatology Center, Richmond Hill

M2M 4J5

Bayview North Dermatology Clinic, Toronto

M5S 3B4

G. Daniel Schachter Medicine Professional Corporation, Toronto

N2J 1C4

K. Papp Clinical Research Inc, Waterloo

N8W 5L7

Windsor Clinical Research Inc., Windsor

H2K4L5

Innovaderm Research Inc., Montreal

J7Z 3B8

Dre Angélique Gagné-Henley M.D. Inc, Saint-Jérôme

H3Z 2S6

Siena Medical Research Corporation, Westmount

All Listed Sponsors

lead

Xenon Pharmaceuticals Inc.

INDUSTRY